Product
LBVD
1 clinical trial
6 indications
Indication
DiphtheriaIndication
TetanusIndication
PertussisIndication
Hepatitis BIndication
PoliomyelitisIndication
Haemophilus influenzae type B infectionClinical trial
A Prospective, Multi-national, Multi-center, Open-label, Randomized, Active-controlled, Parallel-group, Operationally Seamless Phase 2/3 Clinical Study to Evaluate the Immunogenicity and Safety of LBVD, a Fully Liquid Hexavalent Diphtheria-Tetanus-Whole Cell Pertussis-Hepatitis B-poliomyelitis (Inactivated)-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, Given to Healthy Infants at 6-, 10-, and 14-week of Age as Primary SeriesStatus: Not yet recruiting, Estimated PCD: 2025-09-30